Investors & Media

Investor Relations



NASDAQ: TGTX
Price
11.55
Change
+ 0.05
Day High
11.70
Day Low
11.15
Volume
876,974
4:00 PM ET on Sep 20, 2017
Stock price graph
     

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has a pre-clinical program to develop IRAK4 inhibitors, also for B-cell malignancies and autoimmune diseases. TG Therapeutics is headquartered in New York City.

Currently, TG Therapeutics uses the following social media channels:
- Twitter
- Facebook

View all »   RSSRecent Releases

Sep 15, 2017
TG Therapeutics, Inc. Announces the Phase 3 ULTIMATE Trials Evaluating TG-1101 in Patients with Multiple Sclerosis Are Now Open for Enrollment

Sep 5, 2017
TG Therapeutics Announces Completion of Target Enrollment in the UNITY-CLL Phase 3 Trial